Moderna And Merck Announced The First Presentation Of Results From A Planned Analysis From The Phase 2B KEYNOTE-942/mRNA-4157-P201 Study Of mRNA-4157 (V940) Plus Keytruda In Patients With Resected High-risk Melanoma Following Complete Resection (N=157)
Portfolio Pulse from Benzinga Newsdesk
Moderna and Merck announced positive results from a Phase 2B study of mRNA-4157 (V940) plus Keytruda in patients with resected high-risk melanoma. The combination treatment showed significant improvements in recurrence-free survival and distant metastasis-free survival compared to Keytruda alone.
June 03, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's Keytruda, in combination with Moderna's mRNA-4157 (V940), demonstrated significant improvements in survival metrics in a Phase 2B study for high-risk melanoma.
The positive study results are likely to enhance the market perception of Keytruda's efficacy, potentially driving Merck's stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Moderna's mRNA-4157 (V940) in combination with Merck's Keytruda showed significant improvements in survival metrics in a Phase 2B study for high-risk melanoma.
The positive results from the Phase 2B study are likely to boost investor confidence in Moderna's oncology pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100